Alpha DaRT Recurrent GBM Trial: Now Enrolling at Ohio State

Two pieces of news from the past several months deserve more attention than they've gotten — and together they point toward a GBM research landscape that is genuinely moving in new directions.

The first: the FDA has cleared a novel US pilot study testing an alpha-radiation device directly inside recurrent GBM tumors, and that study is now enrolling. The second: the field's most focused scientific gathering on brain cancer convenes in Philadelphia in March 2026.

Here's what each development means for patients.

Alpha DaRT recurrent GBM trial: FDA cleared, now enrolling at Ohio State

In April 2025, Alpha Tau Medical announced the FDA approved an Investigational Device Exemption (IDE) for a pilot study of their Alpha DaRT technology in patients with recurrent glioblastoma. The trial (NCT06910306) is now actively recruiting at Ohio State University Medical Center in Columbus, Ohio.

An IDE is the device equivalent of an Investigational New Drug (IND) clearance — it's the FDA's permission to begin a clinical investigation of a medical device in the US. It is not device approval; it means the FDA reviewed the preclinical data and study design and determined the study can proceed. Alpha DaRT previously received FDA Breakthrough Device Designation, reserved for technologies that may offer meaningful advantages where current options are inadequate.

What is Alpha DaRT and how does it work

Alpha DaRT stands for Diffusing Alpha-emitter Radiation Therapy. Unlike conventional radiation therapy — which uses external X-ray beams directed at the tumor from outside the body — Alpha DaRT works by implanting small radioactive seeds directly inside the tumor.

The seeds release radium-224, which in turn releases short-lived atoms that diffuse through tumor tissue over a range of a few millimeters, delivering concentrated alpha radiation from within. Alpha particles cause more damage to cancer cells per unit of energy than X-rays, but they travel only 50 to 100 micrometers — which limits their reach. Alpha DaRT turns that limitation into a feature: high-intensity radiation, precisely where you want it, with limited exposure to surrounding healthy brain.

Who is eligible for the Alpha DaRT GBM pilot study

The pilot study is small by design — enrolling up to 10 patients in the US. This is a feasibility and safety study, not a late-stage efficacy trial. The goal is to confirm the procedure is safe and the seeds can be accurately placed.

Eligibility includes:

• Adults aged 18–85 with histologically confirmed WHO Grade IV GBM (including gliosarcoma variants)
• Recurrent disease after prior standard radiation (50.4–60 Gy with concurrent temozolomide)
• A single, enhancing tumor recurrence of 3 cm or less in maximum diameter
• Patients not eligible for surgical resection — due to tumor location, medical risk, or patient preference
• At least 4 months elapsed since completing prior radiation

That last criterion is particularly significant. Many patients with recurrent GBM are told their tumor is in a location that makes surgery too dangerous. Alpha DaRT was specifically designed for tumors that can't easily be removed — targeting a group with very limited options.

AACR Brain Cancer conference: what to watch in March 2026

On March 23–25, 2026, the American Association for Cancer Research (AACR) will hold its Special Conference in Cancer Research: Brain Cancer in Philadelphia, Pennsylvania.

This is one of the most concentrated gatherings of brain tumor researchers and clinicians in the world, focused specifically on CNS malignancies. The AACR Brain Cancer conference is where unpublished data gets its first major public hearing — abstracts were due in January 2026, meaning researchers have committed to presenting results that may not yet be public.

Historically, conferences like this surface early survival data from Phase 1/2 trials in immunotherapy, CAR-T, and targeted agents for GBM; updates on biomarker-defined subpopulations (MGMT, IDH, EGFR, H3 mutations); and presentations on tumor microenvironment research shaping what the next generation of trials will test.

For patients and caregivers, major conference results often directly affect which trials open, which drugs advance toward Phase 3, and what oncologists start recommending. We'll be covering key results from AACR Brain Cancer 2026 in a dedicated post as soon as data is presented.

What This Means for Patients

The Alpha DaRT IDE approval is meaningful for a specific, underserved group: patients with small, recurrent GBM tumors that aren't amenable to repeat surgery. If that describes your situation, NCT06910306 at Ohio State may be worth a conversation with your oncologist. The study is small and the technology is early-stage — outcomes are not yet known. But access to a novel approach when few alternatives exist is exactly what pilot studies are designed to provide.

The AACR Brain Cancer conference matters to the broader GBM community. Results presented in Philadelphia in March will influence which trials open in 2026 and beyond, which drugs attract investment for larger studies, and which biomarker-defined populations get the most research attention.

How to take action

• Alpha DaRT GBM pilot study: Review the full listing at NCT06910306 on ClinicalTrials.gov. The enrolling site is Ohio State University Medical Center in Columbus, Ohio.
• AACR Brain Cancer 2026: Follow the AACR at aacr.org and check back here for post-conference coverage.
• Find trials matched to your profile: Use PACT AI to search open GBM trials by diagnosis, biomarker status, and location — including early-stage studies like this one.

Have questions? Reach out at contact@pact-ai.com.

Frequently asked questions

What is the Alpha DaRT trial NCT number for recurrent GBM?

The Alpha DaRT recurrent GBM pilot study is NCT06910306. It is currently enrolling at Ohio State University Medical Center in Columbus, Ohio. Full eligibility criteria and contact information are at ClinicalTrials.gov.

Is Alpha DaRT FDA approved for glioblastoma?

No. Alpha DaRT is not FDA approved. The FDA has cleared an Investigational Device Exemption (IDE) allowing a small pilot study to proceed in patients with recurrent GBM. FDA approval would require additional clinical evidence from larger trials.

What does FDA Breakthrough Device Designation mean?

Breakthrough Device Designation is granted to devices that may offer more effective treatment of serious conditions where current options are inadequate. It provides more intensive FDA guidance during development but is not an approval and does not guarantee the device will ultimately be approved.

When will AACR Brain Cancer 2026 results be available?

The AACR Special Conference in Cancer Research: Brain Cancer runs March 23–25, 2026 in Philadelphia. Results will typically be covered by medical news outlets and summarized by AACR immediately following the conference.

---

This post is for informational purposes only and does not constitute medical advice. Always consult your oncologist or a qualified healthcare provider before making treatment decisions.